INTRODUCTION
Autoimmune pancreatitis (AIP) is a fibroinflammatory condition characterized by tumefactive lesions, a dense lymphoplasmacytic infiltrate rich in IgG4-positive plasma cells, storiform fibrosis and often but not always, elevated serum IgG4 concentrations [1] . Although Yoshida et al discovered similar pathology a ecting the pancreas in Japan in 1995 and coined the term autoimmune pancreatitis (AIP) [2] , the clinical characteristics of this condition were described as early as 1961 [3] . e disease was not recognized as a systemic disease until 2003, when extrapancreatic manifestations were identi ed in patients with AIP [4] . is has resulted in a change in nomenclature to IgG4 associated systemic disease (ISD), which encompasses all diseases associated with a positive IgG4 serology or histology.
ere has been increasing evidence that AIP/ISD exists in nonJapanese populations [5] . To aid diagnosis of this condition, various criteria have been derived by di erent groups. More recently, AIP caused by neutrophilic granulocyte in ltration and not related to IgG4 has been reported in the Western World [6] . Chari et al referred to IgG4 related AIP as type I (with lymphoplasmacytic in ltrate) and granulocyte lesions (non IgG4 related) of AIP as type II (idiopathic duct centric type with granulocyte epithelial cells) [7] . We report our experience in the diagnosis and management of this condition in the North East of England including long term follow up. 
METHODS

Freeman hospital is a tertiary care hospital in North East
England and is the regional referral centre for benign and malignant pancreatobiliary diseases. All patients seen in our hospital and diagnosed with AIP from January 2005 to August 2013 were included in the study. ere are at least three wellknown sets of criteria, i.e. Japanese [8] , Korean [9] and Mayo Clinic criteria [10] for diagnosing ISD/AIP. For the purposes of this study, we have applied the Mayo clinic revised HISORt criteria ("HISORt" for histology, imaging, serology, other organ involvement and response to corticosteroid therapy) and the International Consensus Diagnostic Criteria (ICDC) for diagnosis of our patients [10] . Type I and Type II were also de ned by the criteria set by Sugumar et al [7] .
Data were obtained from a prospectively maintained database of all patients referred to our unit with suspected AIP. Data collected included the age, sex, date of diagnosis, IgG4 levels at time of diagnosis and follow up, CA19-9 levels before and a er treatment and longterm follow up data. All patients underwent contrast enhanced computed tomogram (CT) scan as the baseline investigation ( Fig.  1 ). Some patients who were referred to our hospital from regional hospitals had also undergone magnetic resonance cholangiopancreatogram (MRCP) and endoscopic retrograde cholangiopancreatography (ERCP). MRCP was mainly used to document biliary and pancreatic strictures (Fig. 2) . When clinically indicated, patients also underwent endoscopic ultrasound (EUS) examination to image the pancreas and EUS-guided ne needle aspiration (FNA) if necessary. Patients were managed according to standard clinical practice till the diagnosis of ISD was investigated and con rmed. All patients were discussed in a dedicated hepatobiliary and pancreatic multidisciplinary meeting to ensure the correct diagnosis. Following con rmation of diagnosis as per the HISORt criteria, the patients were commenced on prednisolone 40mg per day in selected patients. e dosage of the steroids was gradually tapered over 4-6 weeks. Treatment response was assessed by improvement in patient᾽s symptoms, liver function tests (LFT), serological and radiological parameters. Azathioprine was the rst line for treatment failures or relapses following steroid withdrawal. If the patients were steroid resistant or azathioprine intolerant, other forms of immunosuppression were considered. Radiological investigations were repeated a er 8 -10 weeks or sooner to ensure improvement of ndings. All patients have been followed up to date.
RESULTS
Autoimmune pancreatitis was diagnosed in 22 patients during the study period. All our patients met at least 3 of the 5 HISORt diagnostic criteria. Six patients met 3 criteria, 10 patients met 4 criteria and one patient all 5 criteria (Table I) . If the ICDC was applied, 20 patients had de nite Type 1 AIP, 1 patient had probable Type 1 AIP and 1 patient had de nite Type II AIP. ere were 21 male and 1 female patients. e mean age of the group was 64.8 years (range: 43-84). All patients, except one (an Asian Indian) were Caucasians. e main presenting symptoms were abnormal LFTs without jaundice (17 patients), weight loss (9), acute abdominal pain without hyperamylasemia (6), vomiting (3), lethargy (1), itching (1) and altered bowel habits (1 patient). e initial diagnoses considered at presentation were autoimmune pancreatitis (10) , pancreatic cancer (6), cholangiocarcinoma (3), chronic pancreatitis (1), primary sclerosing cholangitis (1) and retroperitoneal sarcoma (1) . One patient with Sj gren᾽s syndrome had anticentromere antibodies and another patient was anti-Ro and anti-La positive. Four patients underwent surgery. Two of them had surgery for chronic pancreatitis and a mass in the pancreatic head, suspicious of pancreatic cancer; one had emergency gastro-enterostomy for duodenal obstruction and one had a hepatico-jejunostomy and pancreatic biopsies as part of a palliative procedure for suspected locally advanced inoperable pancreatic malignancy. ree patients underwent laparoscopic pancreatic biopsy for diagnostic con rmation. Histological examination of the resected/biopsy specimen was pathognomonic for AIP in all these cases (Fig. 3a) .
Extrapancreatic involvement consisted of bile duct strictures (14 patients), gall bladder and peripancreatic in ltration (2), duodenal in ltration and obstruction (1), stomach wall (1) pericardial involvement (1); renal/pleural involvement (1) and retroperitoneal brosis (2 patients). Association with other autoimmune diseases was also noted: Sj gren's syndrome (1 patient) and Raynaud's disease (1 patient).
e radiological ndings of CT and MRCP are summarized in Table I . CT ndings documented an enlarged head of pancreas (11 patients) ( Fig. 1) , enlarged body/tail/uncinate process of pancreas (7 patients), thickening/stricturing of extrahepatic bile ducts with dilatation and increased uptake of contrast (11 patients), intrahepatic bile duct structuring/ dilatation and thickening (10 patients), focal pancreatitis (1), gall bladder mass (2), mass in the mesentery (1) and pancreatic calci cation (2 patients). Eight patients also had MRCP for investigation for obstructive jaundice. All of them had di use intra and extrahepatic stricturing of the bile ducts with increased uptake of gadolinium contrast by the duct walls. Five patients had ERCP performed elsewhere prior to referral for management of obstructive jaundice. All 5 of them had extrahepatic biliary strictures ( Fig. 2a ) and 4 had plastic stent insertions at the procedure. Biliary brushings were not speci cally stained for IgG4 cells and were inconclusive with no evidence of malignancy. Endoscopic ultrasound (EUS) was performed in 12 patients. Seven patients had a di usely enlarged head of the pancreas (HoP), 1 had a retroperitoneal mass, 4 had some EUS features of chronic pancreatitis (calci cation, hyperechoic stranding, hypoechoic areas), 1 had a mass in HoP, 1 had atrophic pancreas. Seven patients were documented to have a di use thickening of the common Fig. 3 a, b ). e nal diagnosis was Type I AIP (21 patients), Type II AIP (1 patient); 5/22 (23%) were diagnosed as being diabetic on presentation and 9/22 (41%) had exocrine insu ciency based on low fecal elastase levels. Eighteen patients (82%) were initiated on steroids. Eleven patients had an elevated bilirubin (mean 123 mmols/L; range 42-289). Elevated total IgG was found in 10 patients (26.2 g/L, range: 15.8 -42) and elevated IgG4 (10.69; range 2.76-31) in 10/13 patients in the subgroup receiving steroids. e remaining four patients did not require any steroid therapy as they had sel imiting disease.
Follow up data
All patients have been followed up to date. e mean follow up period was 36.94 months (7-94 months). All 18 patients experienced alleviation of symptoms (abdominal pain or discomfort, fatigue) within 2 weeks of steroid initiation. Twelve patients with abnormal LFTs had normal LFTs by the fourth week. Four patients had sub-optimal response. e rst patient did not show complete resolution of LFTs with steroids and Azathioprine was initiated with a resolution of LFTs subsequently on follow-up (Fig. 2b ). e second patient was only partially steroid responsive from the outset and was treated with Azathioprine, 6-Mercaptopurine and Mycophenolate Mofetil. is patient developed chronic liver disease and portal hypertension due to secondary biliary cirrhosis. He was taken off immunosuppression due to chronic encephalopathy and was on low dose steroids. He unfortunately died due to end stage liver failure. Five patients (25%) relapsed a er steroid withdrawal and all of them were successfully managed with the initiation of Azathioprine. No pancreaticobiliary malignancies were diagnosed in the follow up period. e patients who had elevated CA 19-9 levels have normal values a er treatment and none of them developed malignancy during the follow up period.
DISCUSSION
Autoimmune pancreatitis is a condition which was rst reported in Japan and its existence in the western world was debated until recently [4, 11] . is paper adds to the available data from the United States [5, 10, 12, 13] and Europe [14] [15] [16] and supports the fact that this condition is not con ned to certain geographical regions in the world. ere has been a case series from the UK in the literature [17] and patients from the UK have been reported as part of large multicentre series [18] . ough our rst case was diagnosed in 2005, there has been increased awareness of this condition, which has resulted in a gradual increase in the diagnosis. e mean age of presentation (64 years) and male preponderance is similar to the published literature [10, 19] . The commonest clinical presentation of patients with AIP is either jaundice or abnormal LFTs associated with weight loss. In our series, 77 % (17 patients) presented with jaundice and 73 % (16 patients) had cholestasis (LFTs) at presentation.
Elevated IgG4 levels at presentation were documented in 64% in our series, similar to the previous series from UK (17) . Another large series from Korea reported elevated IgG4 levels in 47% of their patients with AIP [20] . e sensitivity of elevated IgG4 levels in diagnosing ISD is reported to be between 64% and 95% [17, 21, 22] . Although the Japanese studies report that IgG4 elevation is highly speci c and sensitive for AIP [22] , raised serum IgG4 is also seen in pancreatic cancer and other forms of chronic pancreatitis [12] . Elevation of IgG4 levels (<2 fold) can be seen in up to 10% of subjects without AIP including pancreatic cancer [23] .
In another study, serum IgG4 levels were also found to be elevated in cholangiocarcinoma and some had a more than 2-fold rise [24] . ese studies reiterate the fact that serum IgG4 levels should never be used in isolation for diagnosis of AIP.
CA 19-9 levels may also be elevated in AIP [20, 25, 26] . In our series, CA 19-9 levels were elevated in 16 (73%) of the patients. Another similar study examining the behavior of CA 19-9 in patients su ering from AIP found elevated levels in 47% of their patients prior to treatment [27] . ese studies propose that elevated CA19-9 is a result of cholestasis, cholangitis or pancreatitis which returns to normal a er steroid treatment [20, 28] but it is vital to ensure that malignancy has been ruled out as it remains the most common cause for an elevated CA19-9.
Autoimmune pancreatitis is most commonly misdiagnosed as pancreatic cancer and it is imperative to di erentiate these conditions to prevent unnecessary surgery [29] . Cancer was suspected initially in patients with AIP in up to 73% of the cases in one study [9] . Indeed, in another Japanese study, 20% of the cases with AIP were misdiagnosed as having pancreatobiliary malignancies [28] . Conversely, experience from the Mayo clinic suggested that up to 15% of patients with pancreatic cancer were misdiagnosed as having AIP on CT imaging alone [29] . In our series, malignancy was suspected in 41% of the patients (pancreatic cancer suspected in 6 and cholangiocarcinoma in 3 patients). In a large Korean series of 67 patients, surgery was carried out for suspected pancreatic cancer in 18% of patients [30] . Four patients (18%) underwent surgery in our series for suspected cancer and two of them had bypass procedures performed (hepatico-jejunostomy and gastroenterostomy) as a part of the palliative operation for suspected locally advanced inoperable pancreatic malignancy. We now have a better understanding and a high level of suspicion in these cases thus avoiding unnecessary surgery in a later period.
Misdiagnosing AIP in patients with cancer is a major worry, as delay in diagnosis is likely to close the already narrow window of curative surgical options in these patients [31] . We discuss all our cases in a multi-disciplinary setting to ensure correct diagnosis. e Mayo HISORt, Japanese, Korean or more recently the ICDC [32] criteria should be followed strictly in patients as these help to di erentiate malignancy from AIP.
Imaging ndings in AIP include presence of focal or di use pancreatic gland enlargement, atrophy and calci cation [33, 34] . e biliary tract is the commonest extrapancreatic site to be involved (in 30-90% of the cases) and although both the intra and extrahepatic bile ducts can be too, the distal common bile duct is the most common site of involvement [33, 34] . Pancreatic gland abnormality on imaging was seen in 90% of patients and biliary involvement was noted in 68% in our series. Another Japanese series noted biliary involvement in 58% of patients [35] . Intrahepatic bile duct stricturing is now being increasingly recognized as a part of AIP [34] . In our series, 41% of patients (9 patients) were demonstrated to have di use intrahepatic strictures at presentation. Patients with AIP have been noted to have long strictures with pre-stenotic dilatation in contrast to primary sclerosing cholangitis where beading and peripheral duct pruning were more common.
Cross sectional imaging, i.e. CT and MR remains the ideal modality to diagnose AIP. However, EUS can also contribute to the diagnosis in selected cases [36] . Endoscopic ultrasound (EUS) features of AIP consist of either di use increase in the size of the pancreas (di use form of AIP) or focal enlargement of a part of the pancreas (focal form of AIP). is may be associated with echogenic interlobular septae, thickened gland border, narrowing/stricturing of the pancreatic duct and a generally poor echo texture of the pancreas. e bile ducts may demonstrate uniform wall thickening ("sandwich pattern" -echo poor intermediate layer with hyperechoic outer and inner layers) and the gall bladder may also be dilated with thickened walls. ere may be enlarged lymph nodes seen along with loss of interface between the pancreas and portal vessels. Buscarini et al [36] also noted that the thickening of the bile ducts and pancreatic ducts and loss of interface of the pancreas with the portal veins were best seen on EUS compared to other radiological modalities. In our series, 55% (12 patients) who underwent EUS demonstrated typical EUS features of duct wall thickening. A suspicion of the diagnosis of AIP was raised at EUS independently in 67% (8 out of 12 patients). O en, the diagnosis of AIP can be di cult using EUS-FNA cytology alone (as in our series) and this may require a larger specimen which can be obtained with EUS-guided biopsy [37] . With newer needles for tissue acquisition, the histopathologists can also stain for IgG4 thereby avoiding unnecessary minor surgery for diagnosis. Newer techniques of molecular analysis utilizing microsatellite loss and K-ras mutation performed on the FNA cytology specimens may help in di erentiating benign from malignant pancreatic masses in the future [38, 39] .
e diagnosis of Type II AIP is controversial and a well documented case has not previously been reported in the UK. e condition was only rst described in 2003 [40] . Autoimmune pancreatitis with neutrophil in ltration in the epithelium of the pancreatic duct (idiopathic duct centric chronic pancreatitis: IDCP, or granulocyte epithelial lesions: GELs) has been reported by American (7) and Italian [41] pathologists. We diagnosed on histopathology one young male patient (43 years) who presented with a mass in the head of the pancreas, and an inconclusive EUS-FNA and subsequently underwent a Whipple's operation, to have IDCP/GEL type of involvement of the pancreas con rming the presence of this condition in the UK.
Autoimmune pancreatitis characteristically responds to steroid therapy. Spontaneous resolution without treatment has also been noted [10] . It is the intense in ammatory component of the disease that responds to steroid therapy; the brosis o en permanently dis gures, damages and sometimes destroys the organ [42] . While structural normalcy appears to be restored sometimes following steroid therapy, it o en results in glandular atrophy with or without pancreatic insufficiency [43, 44] . Although diabetes and steatorrhoea can develop a er AIP, it is unclear if treatment with steroids reduces long-term incidence of pancreatic exocrine and endocrine insu ciency [14] .
Relapse rates (27% in our study) were also no di erent to a long-term follow up data from a large cohort of Japanese patients. Relapse is common (40-53% of patients) and is predicted by the presence of proximal extra-and intrahepatic biliary stricturing and HLA DQβ1 [18] . ere is limited data on the role of immunosuppression in patients with AIP as radiological and clinical improvement may also occur without any treatment and there is no placebo controlled trial available to con rm the bene t of steroids [44] . However, the recently published Mayo treatment algorithm for relapsing AIP may help us guide for treatment but needs to be validated [45] .
The data on mortality directly linked to autoimmune pancreatitis is unclear and one of our patients died due to intractable disease. AIP is a chronic in ammatory disease and, similar to other conditions, a group of these patients should be prone to develop malignancy in the longer term. However, there is very limited data on the incidence of malignancy in AIP. Shiokawa et al [46] reported that patients with AIP are at high risk of having various cancers. e highest risk for cancer in the rst year a er AIP diagnosis and absence of AIP relapse a er successful treatment of the coexisting cancers suggest that AIP may develop as a paraneoplastic syndrome in some patients. More data is required to corroborate this nding.
CONCLUSIONS
Autoimmune pancreatitis is being increasingly recognized in the British population. Extrapancreatic involvement, particularly extrahepatic biliary involvement is a frequent feature. Intrahepatic stricturing is more common than was previously recognized. It is imperative to rst exclude malignancy which is the much commoner diagnosis. Early recognition of this condition can prevent unnecessary interventions. Steroid responsiveness is characteristic but should never be used as a substitute to an aggressive search for malignancy. Serum IgG4 levels are also elevated in patients with pancreatic cancer and chronic pancreatitis. Before initiating steroids a marker should be identi ed that can be followed up to assess objective response during treatment. Diagnosis should always be based on accepted criteria as this signi cantly reduces the chances of missing malignancy. Awareness of this relatively rare condition and a multi-disciplinary team approach will help us to diagnose and treat this condition more e ectively thereby reducing unnecessary interventions.
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